EHA 2022 | Management and outcomes of elderly patients with LBCL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses how the treatment landscape for elderly patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) has evolved over the past few years with the advent of CAR-T therapy. Dr Sureda explains that elderly patients are now included in more clinical trials and a significant proportion can now be cured with second-line axicabtagene ciloleucel (axi-cel). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Honoraria: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Alexion
Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi
Speaker’s Bureau: Takeda
Research support: Takeda, BMS/Celgene
